Abstract: A single diagnostic dose of a chemical agent that can bind with molecular specificity or provide a well characterized molecular effect on a mammalian host (including humans) is provided to a patient between brain scans. The method typically comprises at least one pre-dose scan of the subject followed by a waiting period then a second post-dose diagnostic scan. The diagnostic scans can be conventional in nature or of a multi-modal variety. A comparison, in the form of a difference or ratio, between data or extracted features before versus after the diagnostic dose indicates with molecular specificity the tone in the brain of that subject. The resulting data may be used to assess instances of medical fraud and can be used in back to work decisions for brain and soft tissue injuries for which the determinations have traditionally been somewhat subjective in nature.

Abstract: A system and diagnostic signatures which are derived from the data collected in the system captures multiple streams of biological sensor data for assessing brain health and functionality of a user. The system includes a plurality of biological sensors adapted to collect biological sensor data from the user as well as the ability to stimulate the brain in a variety of sensory, cognitive, physical, and chemical challenges. Several of the biological sensors are accommodated in an electronics module mounted on the user's head.

Abstract: A multi-modal physiological assessment device and method enables the simultaneous recording and then subsequent analysis of multiple data streams of biological signal measurements to assess the health and function of the brain. The multi-modal assessment system includes at least one channel of EEG brainwave data in combination with cognitive information that provide a two-dimensional data stream of (x(t), y(t)) of cognitive information; voice recordings; motion, position, and stability data; galvanic skin conductance; temperature of the subject; pulse-oximetry data, cerebral blood perfusion data, vaso-motor reactivity data, and the like. The collected data is processed to construct candidate features extracted from multiple biological sensor data streams and correlated with multi-modal signatures to identify data indicative of brain health, disease and injury.

Abstract: An approach for providing diagnostic information regarding one or more impacts sustained by one or more users while the one or more users are participating in a team activity is described. A diagnostic platform detects one or more impacts sustained by a user, wherein the user is part of a team with one or more other users engaged in a team activity. The diagnostic platform generates a recommendation for a level of participation of the user, the one or more other users, or a combination thereof in the team activity based on the one or more impacts, a severity level of the one or more impacts, or a combination thereof. The diagnostic platform further presents the recommendation, a representation of the severity level, a representation of the level of participation, or a combination thereof in a user interface.

Abstract: An approach for monitoring a sleeping subject includes receiving an input for specifying an attachment position of a monitoring device attached to a subject, calibrating a resting positioning of the subject based on the attachment position, analyzing sensor information collected from the monitoring device to determine a movement of the subject into a potentially dangerous position with respect to the calibrated resting position, wherein the monitoring device includes an array of sensors including an accelerometer, one or more biometric sensors, or a combination thereof.

Abstract: An approach for providing personalized information regarding one or more physiological conditions associated with a user is described. A personal health platform calculates a minimum value, a maximum value, or a combination thereof for a physiological condition of a user. The personal health platform senses a measured value for the physiological condition from the user. The personal health platform further presents a user interface depicting the measured value relative to the minimum value, the maximum value, a historical measured value for the user, or a combination thereof, wherein the user interface depicts the measured value, the minimum value, the maximum value, or a combination thereof on one or more ring-based graphical elements, and wherein the one or more ring-based graphical elements correspond to a measurement range for the physiological condition.

Abstract: A system for calibrating and/or verifying system performance of a remote portable EEG system having at least one EEG sensor. Embodiments of the invention can provide various reference signals to calibrate and quality control the remote performance of the data acquisition EEG system. In addition a calibration cable connects a reference signal source to the EEG sensors to enable remote calibration and quality control assessment. Further, a diagnostic biomarker is included to assess the state or function of a subject's brain and enables the classification, prognosis, diagnosis, monitoring of treatment, or response to therapy applied to the brain by measuring any one of a list of candidate features extracted from a given cognitive or sensory task, and measuring changes in the EEG feature and task combination over time, among multiple states, or compared to a normative database.

Abstract: The present invention provides transgenic animals having an amyloid precursor protein wherein the amino acids flanking the &bgr; secretase cleavage site are NF and EV. The invention also provides tissues and cell lines derived from such animals. The invention further provides methods of screening candidate compounds to determine whether the compounds can alter the rate of cleavage of amyloid precursor protein by &bgr; secretase.

Abstract: Provided are methods of identifying inhibitors of ?-secretase that employ modified ?-secretase substrates. The modified ?-secretase substrates have ?-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered ?-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1?-P2? of the ?-secretase cleavage site. Many of the modified ?-secretase substrates are more efficient substrates for ?-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by ?-secretase. Recombinant polynucleotide molecules encoding the modified ?-secretase substrates are provided. Antibodies that recognize cleavage products of the modified ?-secretase substrates are provided. Stable cell lines expressing the modified ?-secretase substrates are provided. Transgenic animals expressing the modified ?-secretase substrates are provided.

Abstract: A system and method for assessing the performance of a system for delivering a pharmaceutical agent to a portion of a body. A pair of electrodes are applied to the portion of the body. A pharmaceutical agent is infused into the portion of the body and the electrodes are energized by a signal generator, electrically stimulating the portion of the body. The voltage and current delivered to the portion of the body are measured using a data acquisition system thereby generating electrical parameter data. An immune response, gene expression level or other biological response to the pharmaceutical agent is measured and the electrical test data is correlated with the biological response to assess the performance of the system.

Abstract: The present invention features a chimeric protein containing a &bgr;-lactamase region and either a Vpr region or a Vpx region. The chimeric protein can be packaged into a viral reporter particle, introduced into a cell recognized by the viral particle and provide intracellular &bgr;-lactamase activity.

Abstract: Provided are methods of identifying inhibitors of &bgr;-secretase that employ modified &bgr;-secretase substrates. The modified &bgr;-secretase substrates have &bgr;-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered &bgr;-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1′-P2′ of the &bgr;-secretase cleavage site. Many of the modified &bgr;-secretase substrates are more efficient substrates for &bgr;-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by &bgr;-secretase. Recombinant polynucleotide molecules encoding the modified &bgr;-secretase substrates are provided. Antibodies that recognize cleavage products of the modified &bgr;-secretase substrates are provided. Stable cell lines expressing the modified &bgr;-secretase substrates are provided.

Abstract: A system and method for assessing the performance of a system for delivering a pharmaceutical agent to a portion of a body. A pair of electrodes are applied to the portion of the body. A pharmaceutical agent is infused into the portion of the body and the electrodes are energized by a signal generator, electrically stimulating the portion of the body. The voltage and current delivered to the portion of the body are measured using a data acquisition system thereby generating electrical parameter data. An immune response, gene expression level or other biological response to the pharmaceutical agent is measured and the electrical test data is correlated with the biological response to assess the performance of the system.